The FDA Group's Insider Newsletter

The FDA Group's Insider Newsletter

Share this post

The FDA Group's Insider Newsletter
The FDA Group's Insider Newsletter
RA/QA News Roll: Late July 2023
Copy link
Facebook
Email
Notes
More

RA/QA News Roll: Late July 2023

Here's what's happening at FDA and across the broader life science RA/QA space.

The FDA Group's avatar
The FDA Group
Jul 28, 2023
∙ Paid
3

Share this post

The FDA Group's Insider Newsletter
The FDA Group's Insider Newsletter
RA/QA News Roll: Late July 2023
Copy link
Facebook
Email
Notes
More
Share

This is our biweekly recap of news and industry happenings curated for our paid subscribers. Our goal is to bring you the headline news as well as the stories, research, and insights that might be harder to find.

If you haven’t upgraded to a paid subscription yet, you can do so here.

Here are some key items from the past couple of weeks.

FDA Guidances


  • FDA released an updated version of its guidance on the Qualification of Medical Device Development Tools. The original guidance was published in its final form in August 2017. The recent final version is a few pages shorter, and the changes are mostly minor procedural updates and clarifications.

  • FDA has issued final guidance on CDER's Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality. It outlines the agency's approach to recognizing voluntary consensus standards relevant to pharmaceutical quality.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 The FDA Group, LLC
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More